Vaccinex, Inc. (VCNX)
USD 1.0
(66.67%)
USD 1.0
(66.67%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -16 Million USD | 521.5% |
| 2022 | -107 Thousand USD | -114.64% |
| 2021 | 731 Thousand USD | 1422.92% |
| 2020 | 48 Thousand USD | -85.19% |
| 2019 | 324 Thousand USD | 204.85% |
| 2018 | -309 Thousand USD | -341.43% |
| 2017 | -70 Thousand USD | -134.83% |
| 2016 | 201 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 77 Thousand USD | 118.67% |
| 2024 Q2 | 207 Thousand USD | -4816.88% |
| 2023 FY | 451 Thousand USD | 521.5% |
| 2023 Q1 | 519 Thousand USD | 10280.0% |
| 2023 Q4 | -412.5 Thousand USD | -3650.0% |
| 2023 Q2 | -30 Thousand USD | -105.78% |
| 2023 Q3 | -11 Thousand USD | 63.33% |
| 2022 Q3 | 50 Thousand USD | 192.59% |
| 2022 FY | -107 Thousand USD | -114.64% |
| 2022 Q1 | -41 Thousand USD | -105.07% |
| 2022 Q2 | -54 Thousand USD | -31.71% |
| 2022 Q4 | 5000.00 USD | -90.0% |
| 2021 Q2 | -35 Thousand USD | 99.25% |
| 2021 Q1 | -4.66 Million USD | -9814.58% |
| 2021 FY | 731 Thousand USD | 1422.92% |
| 2021 Q4 | 809 Thousand USD | 122.6% |
| 2021 Q3 | -3.57 Million USD | -10125.71% |
| 2020 Q2 | -4.51 Million USD | 16.45% |
| 2020 Q1 | -5.4 Million USD | -22.63% |
| 2020 Q4 | 48 Thousand USD | 0.0% |
| 2020 FY | 48 Thousand USD | -85.19% |
| 2020 Q3 | 48 Thousand USD | 101.06% |
| 2019 Q2 | 9000.00 USD | 111.11% |
| 2019 FY | 324 Thousand USD | 204.85% |
| 2019 Q4 | -4.41 Million USD | -1213.89% |
| 2019 Q3 | 396 Thousand USD | 4300.0% |
| 2019 Q1 | -81 Thousand USD | 24.3% |
| 2018 Q4 | -107 Thousand USD | -122.92% |
| 2018 FY | -309 Thousand USD | -341.43% |
| 2018 Q3 | -48 Thousand USD | 60.0% |
| 2018 Q2 | -120 Thousand USD | -252.94% |
| 2018 Q1 | -34 Thousand USD | 51.43% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | -70 Thousand USD | 0.0% |
| 2017 FY | -70 Thousand USD | -134.83% |
| 2016 FY | 201 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 9592.965% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -6301.6% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | -2804.537% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | -8891.011% |
| Better Therapeutics, Inc. | -2.72 Million USD | -486.442% |
| Calithera Biosciences, Inc. | -1.38 Million USD | -1055.523% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 3886.029% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 30.171% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | -1466.726% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | -125.663% |
| Galera Therapeutics, Inc. | -259 Thousand USD | -6079.151% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | -30269.274% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | -472.41% |
| Molecular Templates, Inc. | 50.39 Million USD | 131.757% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -13315.483% |
| NexImmune, Inc. | -1.02 Million USD | -1461.409% |
| Orgenesis Inc. | -5.72 Million USD | -179.546% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 37.599% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | -347737.427% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 154.459% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | -3177.399% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -6798.276% |
| Trevena, Inc. | 1.45 Million USD | 1199.931% |
| Vaxxinity, Inc. | -2.23 Million USD | -616.383% |
| Vicapsys Life Sciences, Inc. | - USD | Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | -3152.846% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 137946.684% |